ArticleIndian dermatology online journal2025
Comparison of the Efficacy of Topical Methotrexate 1% gel Versus Topical Betamethasone Dipropionate 0.05% Lotion in the Treatment of Localized Scalp Alopecia Areata in a Tertiary Care Institute of Central India: A Randomized Control Trial.
Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insights into the Diagnostics and Therapeutics of Alopecia Areata-An Indian Context.Indian dermatology online journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe first line of therapy for limited patchy alopecia areata is topical corticosteroids. Recently, topical methotrexate has been found effective in alopecia areata.
objectiveTo compare the efficacy between topical methotrexate and betamethasone dipropionate lotion in the treatment of localized scalp alopecia areata. PATIENTS AND
methodsSeventy patients with localized scalp alopecia areata were randomized by block randomization in a 1:1 ratio to two groups. Group A received methotrexate 1% gel twice daily, and group B received betamethasone dipropionate 0.05% lotion twice daily for 12 weeks or until a hair regrowth score of 5 was achieved.
resultsFifty-six patients completed the trial. In the per-protocol analysis, no significant difference was seen in the decrease in severity of alopecia tool (SALT) score between group A and group B. The median (25 th -75 th percentile) modified hair regrowth scale at 4 weeks and 12 weeks in group A was 1 (0-2) and 4 (3.5-5), respectively. In group B, it was 1 (0-1.5) and 4 (3-5), respectively, with no significant difference between them. Mild and tolerable side effects were seen in both groups. Irritant dermatitis was seen in 31.03% of patients in group A. Itching was reported in 16 patients in group A as compared to 4 patients in group B, which was statistically significant ( P value = 0.002). LIMITATIONS: Few patients were lost to follow-up and patients were not followed up after stopping treatment to assess the long-term treatment response or relapse.
conclusionBoth methotrexate gel and betamethasone lotion are effective and safe treatments for localized alopecia areata, showing comparable overall response rates. However, local side effects are more common with methotrexate gel than with betamethasone lotion. This study suggests that methotrexate gel can be considered one of the topical treatment options for localized alopecia areata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.